# Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section

> **NCT06823180** · PHASE4 · COMPLETED · sponsor: **Liquan Liang** · enrollment: 105 (actual)

## Conditions studied

- Post-surgical Pain

## Interventions

- **DRUG:** Hydromorphone hydrochloride low dose
- **DRUG:** Hydromorphone hydrochloride high dose
- **DRUG:** 0.9% sodium chloride

## Key facts

- **NCT ID:** NCT06823180
- **Lead sponsor:** Liquan Liang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-03
- **Primary completion:** 2025-08-28
- **Final completion:** 2025-08-28
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823180, "Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06823180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*